Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03885167 · ClinicalTrials.gov registry record
Identification of Biomarkers in Spinocerebellar Ataxia 3
A clinical trial of Spinocerebellar Ataxia Type 3, sponsored by University of Michigan.
- Completed
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT03885167: Completed study of Spinocerebellar Ataxia Type 3, sponsored by University of Michigan.
NCT03885167 is a study of Spinocerebellar Ataxia Type 3 that has completed, run by University of Michigan. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03885167, a study of Spinocerebellar Ataxia Type 3, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers. The goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for treatment or prevention of this condition.
Primary Outcome
A lumbar puncture is performed to collect CSF.
Conditions Studied
Interventions
- OTHER Specimen Collection
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2023-01-04 |
What the finished NCT03885167 record still lists
NCT03885167 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 1 condition, with Spinocerebellar Ataxia Type 3 appearing as the primary indexed condition, and to 1 intervention - of which Specimen Collection is the first listed.
NCT03885167 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03885167 about?
NCT03885167 is a clinical study titled "Identification of Biomarkers in Spinocerebellar Ataxia 3". The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers. The goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for...
What is the current status of trial NCT03885167?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2019-02-21. Estimated completion is 2023-01-04.
What conditions does trial NCT03885167 study?
This clinical trial studies the following conditions: Spinocerebellar Ataxia Type 3.
What interventions are being tested in trial NCT03885167?
The interventions under investigation include: Specimen Collection (OTHER).
Who is sponsoring clinical trial NCT03885167?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03885167 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinocerebellar Ataxia Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI